Tumor-agnostic drug development Journal Article


Authors: Offin, M.; Liu, D.; Drilon, A.
Article Title: Tumor-agnostic drug development
Abstract: Therapies designed to target cancers that harbor specific molecular signatures have reshaped the landscape of oncologic drug development, and advances in next generation sequencing have led to an increase in the identification of these alterations across tumor types. Tumor-agnostic trial designs, such as the "basket trial," have been developed as an approach to study the efficacy of these treatments and increase patient access, especially for patients whose tumors carry these alterations infrequently. We review key aspects of these genomically enriched trial strategies and their impact on drug development and approval.
Keywords: signal transduction; genetics; mutation; antineoplastic agents; clinical trials as topic; antineoplastic agent; neoplasm; neoplasms; metabolism; drug effect; drug discovery; drug development; tumor marker; gene expression regulation; gene expression regulation, neoplastic; clinical trial (topic); procedures; humans; human; biomarkers, tumor
Journal Title: American Society of Clinical Oncology Educational Book
Volume: 38
ISSN: 1548-8756
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-23
Start Page: 184
End Page: 187
Language: English
DOI: 10.1200/edbk_200831
PROVIDER: scopus
PUBMED: 30231313
PMCID: PMC7506519
DOI/URL:
Notes: Am Soc Clin Oncol Educ Book -- Export Date: 2 January 2019 -- Article -- Source: Scopus C2 - 30231313
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alexander Edward Drilon
    633 Drilon
  2. Dazhi   Liu
    45 Liu
  3. Michael David Offin
    170 Offin